Loading...
Docoh

Revance Therapeutics (RVNC)

Utility
Methods of Treatment for Cervical Dystonia
31 Mar 22
This invention provides methods to treat or prevent cervical dystonia, a disorder related thereto, or a symptom thereof, with novel injectable compositions comprising botulinum toxin that may be administered to a subject suffering from such maledy.
Curtis L. Ruegg, Jacob M. Waugh
Filed: 9 Dec 21
Utility
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect
3 Mar 22
This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes.
Curtis L. Ruegg, Jacob M. Waugh
Filed: 10 Sep 21
Utility
Albumin-Free Botulinum Toxin Formulations
28 Oct 21
This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients.
Stewart A. Thompson, Curtis L. Ruegg, Jacob M. Waugh
Filed: 18 May 21
Utility
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
7 Oct 21
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
Gary E. Borodic
Filed: 19 Apr 21
Utility
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
16 Sep 21
A method of treating depression includes identifying a subject with a pain syndrome for increased responsiveness to the treatment of pain associated with the pain syndrome with botulinum toxin and locally administering a botulinum toxin subcutaneously to a face of the subject, thereby treating said pain.
Gary E. Borodic
Filed: 24 Feb 21
Utility
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
19 Aug 21
A method of treating anxiety disorder comprising the steps of: identifying a subject with one or more symptoms of an anxiety disorder; a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the grouop consisting of: transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of anxiety disorder.
Gary E. Borodic
Filed: 28 Dec 20
Utility
Methods and Kits for Topical Application, Removal, and Inactivation of Therapeutic or Cosmetic Toxin Compositions
24 Jun 21
This invention related to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions.
JACOB WAUGH, Curtis Ruegg
Filed: 7 Dec 20
Utility
Transmucosal Botulinum Toxin Compositions, Kits, and Methods for Treating Bladder Disorders
3 Jun 21
The present invention provides methods, compositions, and kits for treating bladder disorders or conditions, in which botulinum toxin is topically administered to the mucosal inner lining or urothelium of the bladder, of a subject in need thereof, for transmucosal delivery across the urothelium to surrounding bladder wall musculature and/or neuronal tissue.
Sunita Babbar, Curtis L. Ruegg
Filed: 28 Aug 18
Utility
Compositions and Methods for Topical and Diagnostic and Therapeutic Transport
11 Mar 21
Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF.
Michael D. Dake, Jacob M. Waugh
Filed: 20 Nov 20
Utility
Botulinum Toxin Formulations and Methods of Use Thereof In Plantar Fascitis with Extended Duration of Effect
16 Dec 20
This invention relates to injectable and transdermal compositions comprising botulinum toxin and their methods of use in administering botulinum toxin to treat or manage plantar fasciitis, a disorder related thereto, or a symptom thereof.
Roman Rubio
Filed: 4 Nov 18
Utility
Injectable Botulinum Toxin Formulations and Methods of Use Thereof Having High Response Rate and Long Effect Duration
9 Dec 20
This invention provides injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes.
Roman Rubio
Filed: 3 Dec 18
Utility
Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
7 Dec 20
Methods of using botulinum toxin based pharmaceuticals are disclosed.
Gary E. Borodic, Martin A Acquadro
Filed: 2 Nov 15
Utility
Compositions and Methods for Safe Treatment of Rhinitis
4 Nov 20
Methods for treating rhinitis in a subject are provided herein.
Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
Filed: 10 Feb 19
Utility
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
2 Sep 20
Methods and systems for chromatographically purifying a botulinum neurotoxin are provided.
Curtis L. RUEGG
Filed: 1 Dec 19
Utility
Compositions and methods for topical application and transdermal delivery of botulinum toxins
17 Aug 20
Improved formulations for transdermal delivery of botulinum toxin are disclosed.
Michael D Dake, Jacob M Waugh
Filed: 23 Sep 18
Utility
CorrectedTopical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
15 Jul 20
A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures.
Gary E. Borodic
Filed: 25 Feb 18
Utility
Injectable Botulinum Toxin Formulations
8 Jul 20
This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes.
Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
Filed: 16 Oct 19
Utility
Methods of Treatment for Cervical Dystonia
10 Jun 20
This invention provides methods to treat or prevent cervical dystonia, a disorder related thereto, or a symptom thereof, with novel injectable compositions comprising botulinum toxin that may be administered to a subject suffering from such maledy.
Curtis L. Ruegg, Jacob M. Waugh
Filed: 17 May 18
Utility
Compositions and Methods for Topical and Diagnostic and Therapeutic Transport
1 Apr 20
Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF.
Michael D. Dake, Jacob M. Waugh
Filed: 6 Jan 19
Utility
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
11 Mar 20
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
Gary E. Borodic
Filed: 11 Nov 19
Patents are sorted by USPTO publication date, most recent first